Press release
Biosimilar Monoclonal Antibodies Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts
Biosimilar Monoclonal Antibodies
What Is the Expected Biosimilar Monoclonal Antibodies Market Size During the Forecast Period?
The biosimilar monoclonal antibodies market has seen rapid growth in recent years. It will increase from $8.04 billion in 2024 to $9.25 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The market's growth is driven by patent expirations, rising awareness of biosimilars, government initiatives, increased investment from pharmaceutical companies, and growing acceptance of biosimilars by both clinicians and patients.
The biosimilar monoclonal antibodies market is expected to see strong growth, reaching $12.79 billion by 2029 with a CAGR of 8.5%. Growth drivers include increasing biologics spending, expansion of biosimilar offerings, and personalized treatment strategies. Key trends involve therapeutic diversification, biobetters, biosimilar autoinjectors, and strategic partnerships.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3412
What Are the High-Growth Segments in the Biosimilar Monoclonal Antibodies Market?
The biosimilar monoclonal antibodies market covered in this report is segmented -
1) By Type: Synthetic Chemicals, Biopharmaceuticals, Other Types
2) By Compound: Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab
3) By Application: Chronic & Autoimmune Diseases, Oncology, Other Applications
Subsegments:
1) By Synthetic Chemicals: Small Molecule Drugs, Chemical Synthesis Products
2) By Biopharmaceuticals: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Other Biopharmaceuticals
3) By Other Types: Antibody-Drug Conjugates, Fusion Proteins, Biosimilars Of Other Biologics
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3412&type=smp
What Key Drivers Are Expected to Influence Future Biosimilar Monoclonal Antibodies Market Growth?
The increasing burden of chronic diseases is driving demand in the biosimilar monoclonal antibodies market. These biosimilars treat conditions like cancer and autoimmune disorders using drugs such as trastuzumab and rituximab. The CDC reported in February 2024 that 42% of Americans suffer from two or more chronic conditions, with 12% managing five or more, illustrating the growing need for such therapies.
Which Companies Hold the Largest Share Across Different Biosimilar Monoclonal Antibodies Market Segments?
Major companies operating in the biosimilar monoclonal antibodies market include Pfizer Inc., Novartis AG, AbbVie Inc., Coherus BioSciences, Biocon Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., BioXpress Therapeutics SA, Intas Pharmaceuticals Limited, Genor BioPharma Co. Ltd., BIOCAD, Dr. Reddy's Laboratories Ltd., 3SBio Inc., Reliance Life Sciences, Hisun Pharmaceuticals, Celgen Biopharmaceuticals, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Shanghai Henlius Biotech Inc., Teva Pharmaceutical Industries Ltd., Alvotech, Xentria Inc., Lazuline Biotech Private Limited, Epygen Biotech Pvt Ltd., Mabpharm Limited, Qilu Pharmaceutical Co. Ltd., Chiatai Tianqing Pharmaceutical Group Co. Ltd., YL Biologics Ltd., Aprogen Biologics, UNDBIO Co Ltd., Samsung Bioepis Co. Ltd., ISU Abxis Corp., Bio-Rad Laboratories Inc.
What Are the Latest Developing Trends in the Biosimilar Monoclonal Antibodies Market?
Major companies in the biosimilar monoclonal antibodies market are working on cost-effective therapies to stay competitive. These biologic products are similar to already approved reference monoclonal antibodies and aim to provide more affordable treatment options for diseases like cancer and autoimmune disorders. For instance, in 2022, Pfizer launched Abrilada, a biosimilar to AbbVie's Humira (adalimumab), offering comparable efficacy and safety while providing significant cost savings for patients and healthcare systems.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodie-global-market-report
What Are the Emerging Geographies for The Biosimilar Monoclonal Antibodies Market Growth?
The countries covered in the biosimilar monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
2. What is the CAGR expected in the Biosimilar Monoclonal Antibodies Market?
3. What Are the Key Innovations Transforming the Biosimilar Monoclonal Antibodies Industry?
4. Which Region Is Leading the Biosimilar Monoclonal Antibodies Market?
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Industry Report 2025-2034: Market Dynamics, Trends, And Forecasts here
News-ID: 4056559 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Biosimilar
Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market
The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023
The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
